PDCD1 and head and neck squamous cell carcinoma: Since similar characteristics were also detected in another HNSCC clinical cohort (Kim et al., 2020), it was still unclear whether the HNSCC subtype with a higher TMB was susceptible to PD-1/PD-L1 therapy.